retatrutide delivery A New Obesity Drug Delivered Surgery-Level Weight Loss in Clinical Trials Retatrutide is coming. Here’s what

doi: 10.1097/MD.0000000000039799 54 AkiyamaHNishimuraAMoritaNYajimaT

The selection of medications, including semaglutide (Ozempic, Wegovy, Rybelsus), liraglutide (Saxenda, Victoza), tirzepatide (Zepbound, Mounjaro), and dulaglutide (Trulicity), was based on clinical appropriateness, insurance coverage, and availability

Learn more about ULTRABRN with these FAQs

They emphasize affordability and transparency in their marketing

Doses listed as Available on the FDAs shortage list are backordered at pharmacies across the country Obesity rates are expected to exceed 50% in the majority of states by 2030 Patients with obesity have, on average, ~$2000 higher healthcare costs per year Obesity is associated with 8 out the 10 leading causes of death and 200 health complications There is a nationwide shortage of healthcare providers, with the problem only expected to worsen (50% are older than 55 years old) There is intense stigma associated with obesity and treatment for the condition in the media, healthcare, socially and professionally Access is unequal